News

VELCADE is indicated for multiple myeloma (MM) and mantle cell lymphoma. The submission contains clinical data from the Phase III VISTA trial comparing the use of VELCADE based

For the second quarter of 2011, the company has generated net income of $13.08m, compared to $22.87m for the same period in 2010. ICON’s income from operations was

The Unifill ready-to-fill (prefilled) syringe is a primary drug container with passive safety features fully integrated within the glass barrel. With Unifill syringe, the undisclosed pharma firm is

Sun Pharma’s alfuzosin hydrochloride extended release tablets are the generic version of Sanofi-aventis’ Uroxatral extended release tablets. Uroxatral is approved to treat signs and symptoms of benign prostatic

Under the agreement, Lonza is responsible to produce materials for Phase 2 trial at its mammalian development and manufacturing plant. IMMUNE claims its human immunoglobulin monoclonal antibody Bertilimumab

The trial aims to evaluate the tolerability, pharmacokinetics (PK) and safety of GLPG0492 on muscle function in healthy volunteers. Earlier, in a Phase I study in healthy volunteers,

Rib-X’s RX-04 program employs a proprietary approach for rational drug design resulting in entirely novel classes of compounds. Recently presented data confirmed the new compounds directly impact ribosome

P2D Bioscience has received a sum of $32,000 for establishing the efficacy of these drugs. The second phase of these studies will investigate the safety and pharmacokinetics of

As per the original agreement, Teva is responsible for marketing and distributing Multikine in Israel and Turkey, while the extended agreement allows Teva to include Croatia and Serbia.